Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

NL0015002CX3
Filter zurücksetzen
Di., 06.01.2026       Qiagen NV
NL0015002CX3

Das Instrument QIA NL0015002CX3 QIAGEN NV EO -,01 EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument QIA NL0015002CX3 QIAGEN NV EO -,01 EQUITY is traded cum capital adjustment on 07.01.2026 and ex capital adjustment on 08.01.2026...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Do., 18.12.2025       Qiagen NV
NL0015002CX3

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion of plans to return approximately $500 million to shareholders through a synthetic share repurchase that combines a direct capital repayment to QIAGEN shareholders with a reverse stock split. QIAGEN announced in November 2025 plans for the repurchase, wh...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Mo., 10.11.2025       Qiagen NV
NL0015002CX3

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the debut of QIAsymphony Connect, the next generation of QIAGEN’s widely adopted automated nucleic acid purification platform, at the 2025 AMP (Association for Molecular Pathology) annual meeting from November 11-15 in Boston. The first public introduction of QIAsymphony Con...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Di., 04.11.2025       Qiagen NV
NL0015002CX3

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the third quarter of 2025 and reaffirmed its outlook for solid profitable growth while raising its profitability targets. QIAGEN reaffirmed its FY 2025 outlook for net sales growth of about 4-5% CER (about 5-6% CER core sales excluding divestments) and raised its...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Di., 04.11.2025       Qiagen NV
NL0015002CX3

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free solutions for single-cell research. The acquisition will significantly expand QIAGEN’s Sample technologies portfolio into the fast-growing single-cell seq...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Di., 04.11.2025       Qiagen NV
NL0015002CX3

Ad-hoc-Mitteilung gemäß Art. 17 Marktmissbrauchsverordnung QIAGEN kündigt CEO-Nachfolge an Venlo, Niederlande, 4. November 2025 – QIAGEN N.V. gibt bekannt, dass Thierry Bernard als Chief Executive Officer und Geschäftsführer zurücktreten wird, sobald ein Nachfolger ernannt worden ist. Der Aufsichtsrat und Thierry Bernard sind übereingekommen, da......
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Di., 04.11.2025       Qiagen NV
NL0015002CX3

    Ad hoc Announcement according to Art. 17 Market Abuse Regulation QIAGEN announces CEO transition plan Venlo, the Netherlands, November 4, 2025 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces that Thierry Bernard will step down as Chief Executive Officer and Managing Director once a successor is appointed. The Superv......
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Di., 04.11.2025       Qiagen NV
NL0015002CX3

Ad hoc Announcement according to Art. 17 Market Abuse Regulation QIAGEN to return approximately $500 million to shareholders through a synthetic share repurchase Venlo, the Netherlands, November 4, 2025 – QIAGEN N.V. announces a plan to return up to approximately $500 million to shareholders through a synthetic share repurchase that combines a di......
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Di., 04.11.2025       Qiagen NV
NL0015002CX3

Ad-hoc-Mitteilung gemäß Art. 17 Marktmissbrauchsverordnung QIAGEN zahlt rund USD 500 Millionen durch einen synthetischen Aktienrückkauf an seine Aktionärinnen und Aktionäre zurück Venlo, Niederlande, 4. November 2025 – QIAGEN N.V. gibt Pläne bekannt, mittels eines synthetischen Aktienrückkaufs bis zu rund $500 Mio. an Aktionärinnen und Aktionäre ......
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Do., 30.10.2025       Qiagen NV
NL0015002CX3

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the EZ2 DNA Investigator Sep&Prep Kit, a fully automated solution for processing sexual assault samples, at the upcoming International Symposium on Human Identification 2025 (ISHI) from November 3-6 in Palm Beach, Florida. Developed specifically for forensi...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 28.10.2025       Qiagen NV
NL0015002CX3

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the 4,000th placement of its QIAcube Connect instrument, a significant milestone in driving automation adoption for sample processing across life science and diagnostic labs. This accomplishment is underscored by the nearly 13,000 cumulative placements of QIAcube platforms global...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Mo., 13.10.2025       Qiagen NV
NL0015002CX3

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025. Press release date / time: Tuesday, November 4, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Wednesday, November 5, at 15:30 Frankfurt time / 14:30 London...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Mi., 10.09.2025       Qiagen NV
NL0015002CX3

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has achieved CE-IVDR certification for its full portfolio of QIAstat-Dx syndromic testing systems and panels, including an expanded Meningitis/Encephalitis (ME) Panel that sets a new benchmark in the diagnosis of central nervous system (CNS) infections. The QIAstat-Dx sys...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Di., 02.09.2025       Qiagen NV
NL0015002CX3

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAstat‑Dx Rise – a version of the QIAstat-Dx automated syndromic testing system that offers unparalled throughput with the easiest workflow available to customers worldwide. The new system, which received clearance from the U.S. Food and Drug Administration (F...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Do., 28.08.2025       Qiagen NV
NL0015002CX3

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. QIAGEN N.V. (NYSE: QG...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Do., 28.08.2025       Qiagen NV
NL0015002CX3

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. QIAGEN N.V. (NYSE: QG...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Do., 28.08.2025       Qiagen NV
NL0015002CX3

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. The Managing Board an...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Do., 28.08.2025       Qiagen NV
NL0015002CX3

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.   Ad-hoc announcement p......
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Do., 28.08.2025       Qiagen NV
NL0015002CX3

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.   Ad-hoc-Mitteilung nac......
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Di., 22.07.2025       Qiagen NV
NL0015002CX3

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its new QIAseq xHYB Long Read Panels, a suite of target enrichment solutions designed to unlock long-read sequencing of genomically complex regions. This new offering strengthens QIAGEN’s position as a provider of differentiated solutions for use on any next-generat...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 08.07.2025       Qiagen NV
NL0015002CX3

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2025. Press release date / time: Tuesday, August 5, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Wednesday, August 6, at 15:30 Frankfurt time / 14:30 London ti...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Mo., 30.06.2025       Qiagen NV
NL0015002CX3

Bitte beachten Sie, dass die Aktie QIAGEN NV EO -,01- ISIN NL0015002CX3 - an der Frankfurter Wertpapierboerse (FWB) am 02.07.2025 ex-Dividende notiert. Clearstream verarbeitet dies entsprechend. Please note that the stock QIAGEN NV EO -,01- ISIN NL0015002CX3 - will be traded ex-dividend on the Frankfurt Stock Exchange (FWB) on July 2, 2025. Clearstream will process this accordingly....
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Mo., 30.06.2025       Qiagen NV
NL0015002CX3

Bitte beachten Sie, dass die Aktie QIAGEN NV EO -,01- ISIN NL0015002CX3 - an der Frankfurter Wertpapierboerse (FWB) am 02.07.2025 ex-Dividende notiert. Clearstream verarbeitet dies entsprechend. Please note that the stock QIAGEN NV EO -,01- ISIN NL0015002CX3 - will be traded ex-dividend on the Frankfurt Stock Exchange (FWB) on July 2, 2025. Clearstream will process this accordingly....
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Do., 26.06.2025       Qiagen NV
NL0015002CX3

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman following the Annual General Meeting of Shareholders (AGM) on June 26, 2025. He succeeds Lawrence A. Rosen, who did not stand for re-election after serving for 12 years on the Supervisory Board. The Dut...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Mi., 25.06.2025       Qiagen NV
NL0015002CX3

Bitte beachten Sie, dass die Aktie QIAGEN NV EO -,01- ISIN NL0015002CX3 - an der Frankfurter Wertpapierboerse (FWB) am 02.07.2025 ex-Dividende notiert. Clearstream verarbeitet dies entsprechend. Please note that the stock QIAGEN NV EO -,01- ISIN NL0015002CX3 - will be traded ex-dividend on the Frankfurt Stock Exchange (FWB) on July 2, 2025. Clearstream will process this accordingly....
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Mi., 25.06.2025       Qiagen NV
NL0015002CX3

Bitte beachten Sie, dass die Aktie QIAGEN NV EO -,01- ISIN NL0015002CX3 - an der Frankfurter Wertpapierboerse (FWB) am 02.07.2025 ex-Dividende notiert. Clearstream verarbeitet dies entsprechend. Please note that the stock QIAGEN NV EO -,01- ISIN NL0015002CX3 - will be traded ex-dividend on the Frankfurt Stock Exchange (FWB) on July 2, 2025. Clearstream will process this accordingly....
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Fr., 20.06.2025       Qiagen NV
NL0015002CX3

Bitte beachten Sie, dass die Aktie QIAGEN NV EO -,01- ISIN NL0015002CX3 - an der Frankfurter Wertpapierboerse (FWB) am 02.07.2025 ex-Dividende notiert. Clearstream verarbeitet dies entsprechend. Please note that the stock QIAGEN NV EO -,01- ISIN NL0015002CX3 - will be traded ex-dividend on the Frankfurt Stock Exchange (FWB) on July 2, 2025. Clearstream will process this accordingly....
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Fr., 20.06.2025       Qiagen NV
NL0015002CX3

Bitte beachten Sie, dass die Aktie QIAGEN NV EO -,01- ISIN NL0015002CX3 - an der Frankfurter Wertpapierboerse (FWB) am 02.07.2025 ex-Dividende notiert. Clearstream verarbeitet dies entsprechend. Please note that the stock QIAGEN NV EO -,01- ISIN NL0015002CX3 - will be traded ex-dividend on the Frankfurt Stock Exchange (FWB) on July 2, 2025. Clearstream will process this accordingly....
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Mi., 18.06.2025       Qiagen NV
NL0015002CX3

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and GENCURIX, Inc. (KOSDAQ: 229000) today announced a new partnership to develop oncology assays for use on the QIAcuityDx platform, a high-performance digital PCR system designed for clinical diagnostics. GENCURIX is the first development partner under QIAGEN’s QIAcuityDx Partnering Program. Th...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
So., 15.06.2025       Qiagen NV
NL0015002CX3

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte’s extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte’s monoclonal ant...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Mo., 02.06.2025       Qiagen NV
NL0015002CX3

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its oncology diagnostics portfolio with two strategic partnerships to advance the use of minimal residual disease (MRD) testing in clinical trials to support pharma co-development projects for companion diagnostics. The new collaborations with Tracer Biotechnologie...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Do., 22.05.2025       Qiagen NV
NL0015002CX3

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality digital PCR (dPCR) assays and customized molecular testing solutions for oncology and other disease areas, to expand the availability of dPCR assays for oncology research ap...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Mo., 12.05.2025       Qiagen NV
NL0015002CX3

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests. The acquisition adds Franklin, Genoox’s flagship cloud-based community platform, to the QIAGEN Digi...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Mi., 07.05.2025       Qiagen NV
NL0015002CX3

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board intends to elect Stephen H. Rusckowski to succeed Lawrence A. Rosen as Chairman of the Supervisory Board following its Annual General Meeting on June 26, 2025. The change comes after Mr. Rosen has decided to step down as Chairman of the Supervisory...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Mi., 07.05.2025       Qiagen NV
NL0015002CX3

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today confirmed strong Q1 2025 results in line with the preliminary announcement and reaffirmed its FY 2025 outlook based on the solid start to the year and evolving macroeconomic trends. As announced on April 6, net sales in Q1 2025 rose 5% to $483 million from Q1 2024, with 7% growth at co...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Mi., 07.05.2025       Qiagen NV
NL0015002CX3

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board will propose the initiation of an annual cash dividend under an amended dividend policy to QIAGEN’s shareholders at the next Annual General Meeting scheduled for June 26, 2025. This milestone reflects QIAGEN’s strategy to introduce a new avenue to i...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Mi., 07.05.2025       Qiagen NV
NL0015002CX3

Ad hoc Announcement according to Art. 17 Market Abuse Regulation QIAGEN to propose initiation of annual cash dividend for shareholder approval at Annual General Meeting Venlo, the Netherlands, May 7, 2025 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces that its Supervisory Board will propose the initiation of an annual cash d......
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Mi., 07.05.2025       Qiagen NV
NL0015002CX3

Ad-hoc-Mitteilung gemäß Art. 17 Marktmissbrauchsverordnung QIAGEN wird Einführung einer jährlichen Bardividende für Aktionäre bei der Hauptversammlung zur Abstimmung bringen Venlo, Niederlande, 7. Mai 2025 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gibt bekannt, dass der Aufsichtsrat den Aktionärinnen und Aktionären auf der nächste......
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Di., 29.04.2025       Qiagen NV
NL0015002CX3

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR (dPCR) workflow that now includes solutions for lentivirus-based applications, commonly used in the production of advanced treatments such as chimeric antigen receptor T-cell (CAR-T), a personal...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Di., 22.04.2025       Qiagen NV
NL0015002CX3

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a series of product and partnership updates designed to strengthen its portfolio for cancer genomic profiling. These new developments will be showcased at the American Association for Cancer Research (AACR) Annual Meeting 2025, from April 25-30 in Chicago. Important updates...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Di., 15.04.2025       Qiagen NV
NL0015002CX3

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that plans are advancing to launch three new sample preparation instruments during 2025 and 2026 to expand and strengthen its portfolio for automated sample preparation. These systems are designed to deliver new levels of efficiency and sustainability for laboratories worldwide an...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Di., 08.04.2025       Qiagen NV
NL0015002CX3

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025. Press release date / time: Wednesday, May 7, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, May 8, at 15:00 Frankfurt time / 14:00 London time / 09:00 New Yo...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
So., 06.04.2025       Qiagen NV
NL0015002CX3

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary Q1 2025 results that exceeded its outlook for both net sales and adjusted earnings per share (EPS), reflecting strong performances across many growth drivers. Net sales grew approximately 5% (+7% at constant exchange rates, CER) to about $483 million in Q1 2025, s...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
So., 06.04.2025       Qiagen NV
NL0015002CX3

Ad-hoc-Mitteilung gemäß Art. 17 Marktmissbrauchsverordnung  QIAGEN kündigt starkes vorläufiges Ergebnis im ersten Quartal 2025 an und hebt die Prognose für den bereinigten Gewinn je Aktie für das Gesamtjahr 2025 Venlo, Niederlande, 6. April 2025 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gibt die vorläufigen Ergebnisse für das erst......
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
So., 06.04.2025       Qiagen NV
NL0015002CX3

Ad hoc Announcement according to Art. 17 Market Abuse Regulation QIAGEN announces strong preliminary Q1 2025 results and updates full-year 2025 adjusted earnings per share outlook Venlo, the Netherlands, April 6, 2025 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces preliminary Q1 2025 results that exceed the outlook for both n......
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
So., 06.04.2025       Qiagen NV
NL0015002CX3

Ad hoc Announcement according to Art. 17 Market Abuse RegulationQIAGEN announces strong preliminary Q1 2025 results and updates full-year 2025 adjusted earnings per share outlook VENLO, THE NETHERLANDS / ACCESS Newswire / April 6, 2025 / QIAGEN N.V. (NYSE:QGEN)(Frankfurt Prime Standard:QIA) announces preliminary Q1 2025 results that exceed the outl...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Di., 01.04.2025       Qiagen NV
NL0015002CX3

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAprep&amp Plasmodium Kit and two companion assays to support malaria research and surveillance efforts. This new solution combines sample preparation and quantitative PCR (qPCR) into a single workflow, providing a rapid and accessible tool for detectin...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Mo., 31.03.2025       Qiagen NV
NL0015002CX3

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2024, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here. QIAGEN will provide printe...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Do., 06.03.2025       Qiagen NV
NL0015002CX3

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, further strengthening its syndromic testing portfolio in the United States. This marks QIAGEN’s second FDA clearance of a QIAstat-Dx panel in 2025, and bui...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink
Mo., 03.03.2025       Qiagen NV
NL0015002CX3

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent infringement, reinforcing its commitment to protecting the scientific advancements behind its proprietary QuantiFERON technology. The complaint, filed in the Local Division of the Court of First Inst...
Zur Nachricht
Qiagen NV
Charts & Research Termsheets Terminal
Permalink